Oramed shareholders approve 2M-share increase to 2019 stock incentive plan at annual meeting

ORAMED PHARMACEUTICALS INC.

Shareholders approved amendment to 2019 Stock Incentive Plan, increasing authorized shares by 2M to 9.5M shares.
All seven director nominees re-elected; votes ranged from 12.5M to 13.0M for, with broker non-votes of ~6.4M.
Auditor Kesselman & Kesselman (PwC Israel) ratified for FY2025 with 19.4M for, 1.4M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.